Clinical and Genotypic Spectrum of Chronic Granulomatous Disease in 71 Latin American Patients: First Report From the LASID Registry
Artículo
Open/ Download
Publication date
2015Metadata
Show full item record
Cómo citar
Oliveira-Junior, Edgar Borges de
Cómo citar
Clinical and Genotypic Spectrum of Chronic Granulomatous Disease in 71 Latin American Patients: First Report From the LASID Registry
Author
- Oliveira-Junior, Edgar Borges de;
- Zurro, Nuria Bengala;
- Prando, Carolina;
- Cabral Marques, Otavio;
- Soeiro Pereira, Paulo Vitor;
- Schimke, Lena-Friederick;
- Klaver, Stefanie;
- Buzolin, Marcia;
- Blancas Galicia, Lizbeth;
- Santos Argumedo, Leopoldo;
- Pietropaolo Cienfuegos, Dino;
- Espinosa Rosales, Francisco;
- King, Alejandra;
- Sorensen, Ricardo;
- Porras, Oscar;
- Roxo Junior, Persio;
- Neves Forte, Wilma Carvalho;
- Orellana, Julio César;
- Lozano, Alejandro;
- Galicchio, Miguel;
- Regairaz, Lorena;
- Grumach, Anete Sevciovic;
- Costa Carvalho, Beatriz Tavares;
- Bustamante, Jacinta;
- Bezrodnik, Liliana;
- Oleastro, Matías;
- Danielian, Silvia;
- Condino Neto, Antonio;
Abstract
Aim. We analyzed data from 71 patients with chronic granulomatous disease (CGD) with a confirmed genetic diagnosis, registered in the online Latin American Society of Primary Immunodeficiencies (LASID) database. Results. Latin American CGD patients presented with recurrent and severe infections caused by several organisms. The mean age at disease onset was 23.9 months, and the mean age at CGD diagnosis was 52.7 months. Recurrent pneumonia was the most frequent clinical condition (76.8%), followed by lymphadenopathy (59.4%), granulomata (49.3%), skin infections (42%), chronic diarrhea (41.9%), otitis (29%), sepsis (23.2%), abscesses (21.7%), recurrent urinary tract infection (20.3%), and osteomyelitis (15.9%). Adverse reactions to bacillus Calmette-Guerin (BCG) vaccination were identified in 30% of the studied Latin American CGD cases. The genetic diagnoses of the 71 patients revealed 53 patients from 47 families with heterogeneous mutations in the CYBB gene (five novel mutations: p.W361G, p.C282X, p.W483R, p.R226X, and p.Q93X), 16 patients with the common deletion c.75_76 del.GT in exon 2 of NCF1 gene, and two patients with mutations in the CYBA gene. Conclusion. The majority of Latin American CGD patients carry a hemizygous mutation in the CYBB gene. They also presented a wide range of clinical manifestations most frequently bacterial and fungal infections of the respiratory tract, skin, and lymph nodes. Thirty percent of the Latin American CGD patients presented adverse reactions to BCG, indicating that this vaccine should be avoided in these patients. (C) 2015 Wiley Periodicals, Inc.
General note
Artículo de publicación ISI
Patrocinador
Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil); Agence Nationale de la Recherche.
Quote Item
Pediatr Blood Cancer 2015;62:2101–2107
Collections
The following license files are associated with this item: